• 学术搜索
  • 科研智能体
    • Research Labs
    • AI 阅读
    • AI 文库
    • 深度研究
    • 学者亮点
  • 学术资源
    • AI2000
    • 期刊/会议
    • 学者库
    • 学术API
      MCP&Skill
    • 溯源树
    • 数据集
  • 知识沉淀
    • 学术空间
订阅小程序
旧版功能
aminer vip
开通会员低至0.73元/天
一次搞定AI科研
立即登录
  • English
  • 联系方式
    I

    Intermountain Healthcare

    EST. 1970
    1,004论文总数
    2.4万引用总数

    Intermountain Healthcare is a not-for-profit healthcare system and is the largest healthcare provider in the Intermountain West of the United States. Intermountain Healthcare provides ambulatory and acute health services, along with other medical services, through 225 clinics and 25 hospitals in Utah, Idaho, Nevada and additional affiliations in other areas. It also offers integrated managed care under the insurance brand "SelectHealth." Intermountain Healthcare is headquartered in Salt Lake City, Utah, and has more than 42,000 employees.Intermountain and Colorado-based SCL Health announced that they completed their merger on April 1st, 2022. The combined system employs than 58,000 people and operates 33 hospitals.

    论文量&引用量时间轴

    机构学者

    论文(1004)

    年份
    起
    –
    止
    排序
    1Increasing HIV Testing During Gonorrhea and Chlamydia Evaluations in Urgent Care and Emergency Departments: A Large Health System Initiative
    Allan M Seibert, Michelle Matheu,Whitney R Buckel,Joseph Bledsoe,Park Willis, Adam Balls,Allison M Butler, Tamara D Moores Todd,Caroline Vines,James Hellewell, Randall Smout,Bert Lopansri,

    Background HIV testing opportunities are often missed during urgent care (UC) and emergency department (ED) evaluations for sexually transmitted infections. We implemented a multimodal diagnostic stewardship intervention to increase HIV testing in UC and ED gonorrhea (GC)/chlamydia (CT) testing encounters ("HIV co-testing"). Methods We conducted a pre-/post implementation study across 26 UCs and 22 EDs in our health system (April 2022-March 2024). The intervention included system-wide simultaneous implementation of provider and patient education and a link-to-care program for newly diagnosed people with HIV (PWH) and patients needing additional testing, followed by phased activation of an electronic health record alert prompting HIV co-testing. We estimated the impact of the intervention on HIV GC/CT co-testing using interrupted time series analysis, measured alert engagement, and described the impact of the link-to-care program. Results By the end of the intervention period, HIV GC/CT co-testing rates were 12.7% points higher in UC (95% CI 6.2-19.2), a 41.9% relative increase (P < .001) compared with preintervention trends. In the ED, co-testing rates rose 12.3% points (95% CI 1.08-23.6), a 53.4% relative increase (P = .02). A total of 4704 alerts fired, resulting in 730 alert-associated HIV co-tests. During the intervention, 17 PWH were newly diagnosed: 5 (29%) were due to alert-associated co-tests. All PWH and those requiring additional testing received prompt linkage to care. Conclusions HIV GC/CT co-testing increased in UC and ED during our intervention, leading to new HIV diagnoses and linkage to care. Integrating HIV co-testing into GC/CT testing encounters improved HIV screening practices in our large health system.

    2026Clinical infectious diseases an official publication of the Infectious Diseases Society of America(2026)引用:1
    引用
    AI阅读
    加入学术空间
    2Clinical Risk Factors Predicting Likelihood of Pathogenic Genetic Result in NICU Patients
    Joshua L Bonkowsky, Samuel B Zoucha, Jenna Jensen,Jacob Wilkes, Rachel N Palmquist, Mark Yandell,Martin Tristani-Firouzi

    Purpose: Children with neonatal intensive care unit (NICU) admission have higher rates of genetic disease, but it is unclear which patients should have genetic testing. Our goal was to identify clinical predictors associated with a pathogenic genetic result in NICU infants. Methods: This was a retrospective, population-based cohort analysis of infants born between January 1, 2009 and June 30, 2011 with a history of NICU admission and subsequent follow-up and genetic testing through 2021. Results: A total of 99 infants met inclusion criteria. In total, 64 (65%) patients had a negative genetic test result; 35 (35%) had a positive (pathogenic) result. Lower birthweight, younger gestational age, longer length of stay, or 2 or more indicators of severe illness were associated with a pathogenic result. Conclusion: Our work suggests that clinical predictors can be used to guide genetic testing in NICU infants. Use of these clinical risk factors could provide a diagnostic care pathway, potentially shortening the diagnostic odyssey and reducing potential morbidities.

    2026Genetics in medicine open(2026)
    引用
    AI阅读
    加入学术空间
    3Exploring Clusters Based on Ultrasound-Detected Inflammation in Patients with Psoriatic Arthritis: a Post-Hoc Analysis from the ULTIMATE Trial
    Maria Antonietta D’Agostino, Philip G Conaghan,Corine Gaillez,Maarten Boers,Esperanza Naredo,Peter Mandl,Philippe Carron, Alejandra López-Rdz,Ruben Burgos-Vargas, Javier Rosa,Catherine Bakewell, Tomas Cazenave,

    Psoriatic arthritis (PsA) is characterized by heterogeneous musculoskeletal manifestations. The aim of this post-hoc cluster analysis from the ULTIMATE study was to explore whether objective assessment of inflammation, using power-Doppler ultrasound (PDUS), identified homogeneous groups of patients based on the level of severity of ultrasound-detected synovitis and then to determine the longitudinal trajectory of response with secukinumab vs. placebo for each cluster up to week 12. The ULTIMATE study enrolled patients with PsA and active clinical and PDUS synovitis. Patients were randomized to either secukinumab 150 or 300 mg, according to psoriasis severity, or placebo for the first 12 weeks. Multiple factor analysis was performed on baseline B-mode and power Doppler (PD) signal core components of the composite Global EULAR-OMERACT synovitis score (GLOESS) at joint level. Three clusters were identified from all patients enrolled in the ULTIMATE study (N = 166), with 49 (30

    2026BMC Musculoskeletal Disorders(2026)
    引用
    AI阅读
    加入学术空间
    4Single-cell Profiling of the Duodenum During Chronic Human Norovirus Infection
    Yuki Matsushima, Jessica R. Durkee-Shock,Derron A. Alves,Bianca M. Nagata,Sun A. Kim, Eunice Ching Chan,Natthawan Chaimongkol,Ryoka Ishiyama,Karenna Barton, Alison Han, Libby A. Kelly, Princess U. Ogbogu,

    Human noroviruses are a major cause of diarrheal disease, yet their pathogenesis remains poorly defined. We performed single-cell RNA sequencing of duodenal biopsies and matched stem cell–derived enteroids from immunodeficient individuals with chronic norovirus infection. Norovirus RNA was detected primarily in enterocytes, enteroendocrine cells, and macrophages, with the highest proportion of viral RNA-positive cells observed among M2 macrophages, followed by late enterocytes. Despite this distribution, late enterocytes produced higher viral yields than differentiated M2 macrophages in vitro. Norovirus infection was associated with the up-regulation of MHC class I-related genes and IL15 in duodenal macrophages and late enterocytes, together with increased IFNG expression by CD8 T cells. Macrophages and late enterocytes up-regulated CXCL9 and CXCL10/11 , respectively, consistent with CD8 and CD4 T cell recruitment to the duodenum. These findings show that noroviruses infect and persist across multiple permissive cell types during chronic infection, resulting in marked dysregulation of innate and adaptive immune responses that may drive pathogenesis.

    2026Science Advances(2026)
    引用
    AI阅读
    加入学术空间
    5Palbociclib in Patients with Ovarian Cancer with CDKN2A Alterations: Results from the Targeted Agent and Profiling Utilization Registry Study.
    Dan S Veljovich,Michael Rothe,Elizabeth Garrett-Mayer, Hussein M Ali-Ahmad,R Wendel Naumann,Jean Siedel,John K Chan, Andrew Gregory,Evan Pisick, Bamidele Adesunloye,Rebecca C Arend,Maria Bell,

    PURPOSE:The Targeted Agent and Profiling Utilization Registry Study is a phase II basket trial evaluating the antitumor activity of commercially available targeted agents in patients with advanced cancer and genomic alterations. Results of a cohort of patients with ovarian cancer (OC) with CDKN2A alterations treated with palbociclib are reported. METHODS:Eligible patients had advanced OC, measurable disease (RECIST), Eastern Cooperative Oncology Group performance status 0-2, adequate organ function, tumors with CDKN2A alterations, and no remaining standard treatment options. The primary end point was disease control (DC), defined as objective response (OR) or stable disease (SD) of at least 16+ weeks duration (SD16+). Simon two-stage design with a null DC rate of 15% versus 35% (power = 0.85; α = .10) was used. Secondary end points included OR, progression-free survival (PFS), overall survival (OS), duration of response, duration of SD, and safety. RESULTS:Twenty-eight patients were enrolled from February 2017 to April 2023, and all had OC with a CDKN2A alteration (loss [n = 21], mutation [n = 5], and loss and mutation [n = 2]). One patient was not evaluable for efficacy because of an excluded genomic finding. Three patients had a partial response and seven had SD16+ for DC and OR rates of 38% (90% CI, 25 to 100) and 11% (95% CI, 2 to 29), respectively. The null hypothesis of 15% DC rate was rejected (P = .004). The median PFS was 8 weeks (95% CI, 8 to 18) and the median OS was 33 weeks (95% CI, 24 to 73). Nineteen patients (68%) had at least one treatment-related grade 3-4 adverse event (AE) or serious AE including anemia, dyspnea, fatigue, leukopenia, neutropenia, and thrombocytopenia. CONCLUSION:Palbociclib met the prespecified criteria to declare a signal of activity in patients with OC and CDKN2A alterations.

    2026JCO precision oncology(2026)
    引用
    AI阅读
    加入学术空间
    立即登录,查看全部 1004 篇论文

    合作机构(100)

    犹他大学合作论文 265
    Intermountain Medical Center,Intermountain Healthcare合作论文 59
    温纳贝戈医学中心合作论文 47
    University of Utah Health Care合作论文 37
    华盛顿大学合作论文 37
    哥伦比亚大学合作论文 36
    斯坦福大学合作论文 33
    科罗拉多州立大学合作论文 26
    密歇根大学合作论文 24
    俄勒冈健康与科学大学合作论文 22

    机构统计